Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

By sjmartinez • March 1, 2023

Clark AS, Hong F, Finn RS, DeMichele AM, Mitchell EP, Zwiebel J, Arnaldez FI, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Copur MS, Kasbari SS, Thind R, Conley BA, Arteaga CL, O'Dwyer PJ, Harris LN, Chen AP, Flaherty KT. Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B. Clin Cancer Res. 2023 Feb 28:OF1-OF7. doi: 10.1158/1078-0432.CCR-22-2150. Epub ahead of print. PMID: 36853016.

Tags: Hematology/Oncology, Publications

Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics

Rodriguez GE, Zhao Y, Nishiga Y, Peprah F, Shen J, Abhiraman GC, Ogishi M, Zhang C, Saco J, Waghray D, Serasanambati M, Torres L, Simone[...]

Yttrium-90 Radioembolization as a Safe and Effective Treatment Option for Hepatic Uveal Melanoma Metastases

Ni JR, Quirk M, Chmielowski B, Padia SA. Yttrium-90 Radioembolization as a Safe and Effective Treatment Option for Hepatic Uveal Melanoma Metastases. Cardiovasc Intervent Radiol.[...]

Advancements in intratumoral therapies for liver tumors

Raman SS, Cutler NR, Sramek JJ, Hecht JR, Finn RS, Anand SR, Chiang J, Lu DS. Advancements in intratumoral therapies for liver tumors. Front Oncol.[...]